57 related articles for article (PubMed ID: 8218945)
1. A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies.
Ghosh AK; Smith NK; Prendiville J; Thatcher N; Crowther D; Stern PL
Eur Cytokine Netw; 1993; 4(3):205-11. PubMed ID: 8218945
[TBL] [Abstract][Full Text] [Related]
2. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects.
Banks RE; Forbes MA; Patel PM; Storr M; Hallam S; Clarke D; Novick D; Ingham E; Bowmer C; Southgate J; Trejdosiewicz LK; Illingworth J; Perren TJ; Selby PJ
Cytokine; 2000 Apr; 12(4):388-96. PubMed ID: 10805221
[TBL] [Abstract][Full Text] [Related]
4. Autologous high-killing cytotoxic T lymphocytes against human lung cancer are induced using interleukin (IL)-1beta, IL-2, IL-4, and IL-6: possible involvement of dendritic cells.
Saijo Y; Hong X; Tanaka M; Tazawa R; Liu SQ; Saijo K; Ohno T; Koike K; Ohkuda K; Satoh K; Nukiwa T
Clin Cancer Res; 1999 May; 5(5):1203-9. PubMed ID: 10353758
[TBL] [Abstract][Full Text] [Related]
5. The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.
Rosenthal NS; Hank JA; Kohler PC; Minkoff DZ; Moore KH; Bechhofer R; Hong R; Storer B; Sondel PM
J Biol Response Mod; 1988 Apr; 7(2):123-39. PubMed ID: 3258904
[TBL] [Abstract][Full Text] [Related]
6. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological effects of single bolus administration of recombinant interleukin-2 in cattle.
Campos M; Hughes HP; Godson DL; Sordillo LM; Rossi-Campos A; Babiuk LA
Can J Vet Res; 1992 Jan; 56(1):10-5. PubMed ID: 1586889
[TBL] [Abstract][Full Text] [Related]
8. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
9. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
11. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
12. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
Bukowski RM; Olencki T; Gunn H; McLain D; Budd GT; Sandstrom K; Tuason L; Redovan C; Rayman P; Tubbs R; Resta D; Elson P; Finke J
Clin Cancer Res; 1996 Feb; 2(2):347-57. PubMed ID: 9816178
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer.
Vokes EE; Figlin R; Hochster H; Lotze M; Rybak ME
Cancer J Sci Am; 1998; 4(1):46-51. PubMed ID: 9467046
[TBL] [Abstract][Full Text] [Related]
16. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
[TBL] [Abstract][Full Text] [Related]
17. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L
Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906
[TBL] [Abstract][Full Text] [Related]
20. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]